Healthcare / Drug Manufacturers - Specialty & GenericSES
$0.39
+0.02 (+6.94%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 35% · confianza 11%
FCF escenarios
weak_data · normalized FCF $-6.8M · quality 26.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
28/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$407M
P/E
0.6x
↓EV/EBITDA
N/A
•ROE
-2778.4%
↓Gross Margin
26.3%
↓Debt/Equity
16.17
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-18.6%
FCF CAGR
—
FCF margin
-51.0%
FCF / Net income
0.39x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $7.8M · net income $-10.1M · FCF $-4.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $7.8M | $7.8M | $6.0M | $5.9M | $14.4M |
| Net Income | $-10.1M | $-10.1M | $-10.8M | $-9.6M | $-4.6M |
| EBITDA | $-9.0M | $-9.0M | $-8.7M | $-8.5M | $-2.8M |
| EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Gross Margin | 26.3% | 26.3% | 17.6% | 39.2% | 85.4% |
| Operating Margin | -80.9% | -80.9% | -124.0% | -142.2% | 8.6% |
| Net Margin | -130.6% | -130.6% | -181.1% | -162.6% | -32.0% |
| Balance Sheet | |||||
| Debt/Equity | 16.17 | 16.17 | 1.20 | 0.27 | 0.22 |
| Current Ratio | 2.31 | 2.31 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-4.0M | $-4.0M | $-6.8M | $-8.4M | $2.9M |
| Returns | |||||
| ROE | -2778.4% | -2778.4% | -248.7% | -60.7% | -23.3% |
| Valuation | |||||
| P/E | 0.61 | 0.61 | — | — | — |
| P/B | 924.72 | 924.72 | 5.48 | 4.34 | 6.50 |
| Growth & Yield | |||||
| Revenue Growth | 30.3% | 30.3% | 0.8% | -58.9% | — |
| EPS Growth | 17.7% | 17.7% | -11.9% | -105.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+1926.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.01 → -0.01
Residual
+1926.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.